ChemWerth, Inc., a global leader in generic active pharmaceutical ingredient (API) development and supply, continues to ...

Foreign API makers unaccustomed to hosting FDA visitors may soon have to get their houses in order. A deal through which generics makers would pay $299 million in annual user fees to the FDA could ...

Biocon refuted media reports that said the company is evaluating a plan to sell its generic active pharmaceutical ingredient (API) business. (Image Credits: Pixabay) Biocon on Friday refuted media ...

With the healthcare landscape continually evolving, the generic medicines industry guarantees widespread access to affordable medications for millions of patients worldwide. Generics play a pivotal ...

According to news report, Biocon is considering selling its generic active pharmaceutical ingredient (API) business, which is valued at approximately $1.5 billion, in order to lower its total debt.

Japan is legendary for its focus—many would say obsession—on producing high-quality products. When it comes to sourcing active pharmaceutical ingredients (APIs), Japanese generic drug firms are ...